Literature DB >> 20807511

Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways.

Emily R Rosario1, Jenna Carroll, Christian J Pike.   

Abstract

Normal, age-related depletion of the androgen testosterone is a risk factor for Alzheimer's disease (AD) in men. Previously, we reported that experimental androgen depletion significantly accelerates development of AD-like neuropathology in the 3xTg-AD triple-transgenic mouse model of AD, an effect prevented by androgen treatment. Because testosterone is metabolized in brain into both the androgen dihydrotestosterone (DHT) and the estrogen 17β-estradiol (E2), testosterone can mediate its effects through androgen and or estrogen pathways. To define the role of androgen and estrogen pathways in regulation of AD-like neuropathology, we compared the effects of testosterone (T) and its metabolites DHT and E2 in male 3xTg-AD mice depleted of endogenous sex steroid hormones by gonadectomy (GDX). Male 3xTg-AD mice were sham GDX or GDX, immediately treated with vehicle, T, DHT, or E2, and 4 months later evaluated for two indices of AD-like neuropathology, β-amyloid (Aβ) accumulation and tau hyperphosphorylation. In comparison to sham GDX mice, we observed a significant increase in Aβ accumulation in GDX mice in subiculum, hippocampus, and amygdala. Treatment of GDX mice with T prevented the increased Aβ accumulation in all three brain regions. DHT treatment yielded similar results, significantly reducing Aβ accumulation across brain regions. Interestingly, E2 prevented Aβ accumulation in hippocampus but exerted only partial effects in subiculum and amygdala. Levels of tau hyperphosphorylation in sham GDX male 3xTg-AD mice were modest and only slightly increased by GDX. Treatment of GDX mice with T or E2 but not DHT reduced tau hyperphosphorylation to levels lower than observed in sham animals. These data suggest that testosterone regulates Aβ pathology through androgen and estrogen pathways and reduces tau pathology largely through estrogen pathways. These findings further define hormone pathways involved in regulation of AD-related pathology, information that is important for understanding disease etiology and developing pathway-specific hormone interventions.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807511      PMCID: PMC2965035          DOI: 10.1016/j.brainres.2010.08.068

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  73 in total

1.  Chemical andropause and amyloid-beta peptide.

Authors:  S Gandy; O P Almeida; J Fonte; D Lim; A Waterrus; N Spry; L Flicker; R N Martins
Journal:  JAMA       Date:  2001-05-02       Impact factor: 56.272

Review 2.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

3.  Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging.

Authors:  Brian J Cummings; Amy J L Mason; Ronald C Kim; Philip C-Y Sheu; Aileen J Anderson
Journal:  Neurobiol Aging       Date:  2002 Mar-Apr       Impact factor: 4.673

4.  Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease.

Authors:  Sozos Ch Papasozomenos; Alikunju Shanavas
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats.

Authors:  Csaba Leranth; Ors Petnehazy; Neil J MacLusky
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

6.  Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons.

Authors:  C J Pike
Journal:  Brain Res       Date:  2001-11-16       Impact factor: 3.252

7.  A role for estrogen receptor beta in the regulation of growth of the ventral prostate.

Authors:  Z Weihua; S Makela; L C Andersson; S Salmi; S Saji; J I Webster; E V Jensen; S Nilsson; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

8.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth.

Authors:  Zhang Weihua; Richard Lathe; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

9.  Order of magnitude differences between methods for maintaining physiological 17beta-oestradiol concentrations in ovariectomized rats.

Authors:  Jakob O Ström; Elvar Theodorsson; Annette Theodorsson
Journal:  Scand J Clin Lab Invest       Date:  2008       Impact factor: 1.713

Review 10.  A role for the androgen metabolite, 5alpha-androstane-3beta,17beta-diol, in modulating oestrogen receptor beta-mediated regulation of hormonal stress reactivity.

Authors:  R J Handa; M J Weiser; D G Zuloaga
Journal:  J Neuroendocrinol       Date:  2009-03       Impact factor: 3.627

View more
  45 in total

1.  Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease.

Authors:  Yasmina Manso; Javier Carrasco; Gemma Comes; Gabriele Meloni; Paul A Adlard; Ashley I Bush; Milan Vašák; Juan Hidalgo
Journal:  Cell Mol Life Sci       Date:  2012-06-22       Impact factor: 9.261

2.  Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease.

Authors:  Sonia George; Géraldine H Petit; Gunnar K Gouras; Patrik Brundin; Roger Olsson
Journal:  ACS Chem Neurosci       Date:  2013-09-25       Impact factor: 4.418

3.  Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.

Authors:  Matej Mihelčić; Goran Šimić; Mirjana Babić Leko; Nada Lavrač; Sašo Džeroski; Tomislav Šmuc
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

Review 4.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

5.  Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology.

Authors:  E Candeias; A I Duarte; I Sebastião; M A Fernandes; A I Plácido; C Carvalho; S Correia; R X Santos; R Seiça; M S Santos; C R Oliveira; P I Moreira
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

Review 6.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

Review 7.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 8.  Low Testosterone Level and Risk of Alzheimer's Disease in the Elderly Men: a Systematic Review and Meta-Analysis.

Authors:  Wenshan Lv; Na Du; Ying Liu; Xinyi Fan; Yunyang Wang; Xiujuan Jia; Xu Hou; Bin Wang
Journal:  Mol Neurobiol       Date:  2015-07-08       Impact factor: 5.590

9.  Sex steroid levels and AD-like pathology in 3xTgAD mice.

Authors:  Cassia R Overk; Sylvia E Perez; Chunqi Ma; Matthew D Taves; Kiran K Soma; Elliott J Mufson
Journal:  J Neuroendocrinol       Date:  2013-02       Impact factor: 3.627

10.  Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease.

Authors:  Anna M Barron; Luis M Garcia-Segura; Donatella Caruso; Anusha Jayaraman; Joo-Won Lee; Roberto C Melcangi; Christian J Pike
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.